Efficacy and Safety of the Oncolytic Herpes Simplex Virus rRp450 Alone and Combined With Cyclophosphamide
Open Access
- 1 May 2008
- journal article
- Published by Elsevier BV in Molecular Therapy
- Vol. 16 (5), 879-885
- https://doi.org/10.1038/mt.2008.49
Abstract
No abstract availableKeywords
This publication has 36 references indexed in Scilit:
- Oncolytic HSV and Erlotinib Inhibit Tumor Growth and Angiogenesis in a Novel Malignant Peripheral Nerve Sheath Tumor Xenograft ModelMolecular Therapy, 2007
- Phase I, Open-Label, Dose-Escalating Study of a Genetically Engineered Herpes Simplex Virus, NV1020, in Subjects with Metastatic Colorectal Carcinoma to the LiverHuman Gene Therapy, 2006
- Cyclophosphamide enhances glioma virotherapy by inhibiting innate immune responsesProceedings of the National Academy of Sciences of the United States of America, 2006
- Malignant peripheral nerve sheath tumors with high and low Ras‐GTP are permissive for oncolytic herpes simplex virus mutantsPediatric Blood & Cancer, 2005
- Oncolytic herpes simplex virus mutants are more efficacious than wild‐type adenovirus Type 5 for the treatment of high‐risk neuroblastomas in preclinical modelsPediatric Blood & Cancer, 2004
- Oncolytic herpes simplex virus vectors for cancer virotherapyCancer Gene Therapy, 2002
- Prodrug bioactivation and oncolysis of diffuse liver metastases by a herpes simplex virus 1 mutant that expresses the CYP2B1 transgeneCancer, 2002
- Regulation of herpes simplex virus γ134.5 expression and oncolysis of diffuse liver metastases by Myb34.5JCI Insight, 2002
- Treatment of High-Risk Neuroblastoma with Intensive Chemotherapy, Radiotherapy, Autologous Bone Marrow Transplantation, and 13-cis-Retinoic AcidThe New England Journal of Medicine, 1999
- An oncolytic viral mutant that delivers the CYP2B1 transgene and augments cyclophosphamide chemotherapyNature Biotechnology, 1998